FeesSafety
Pluang+

Immuneering extends Phase 2 pancreatic cancer trial as patients live longer, accelerates Phase 3 enrollment.

Company Fundamentals
29 Oct 2026, 23:05 WIB
GlobeNewsWire
View Source
Bullish
Immuneering extends Phase 2 pancreatic cancer trial as patients live longer, accelerates Phase 3 enrollment.

Immuneering Corporation reported that patients in its Phase 2 pancreatic cancer trial with atebimetinib combinations are living longer than expected, leading to an extension of the trial and updated data expected in the first half of 2027. Enrollment in the Phase 3 MAPKeeper 301 trial is ahead of schedule, prompting an increase in target enrollment from 510 to 570 patients and potentially accelerating topline data release to mid-2028. The company also updated its cash runway to the fourth quarter of 2028, reflecting trial extensions and commercial preparations. These developments highlight growing medical recognition of atebimetinib's unique mechanism and promising survival benefits in pancreatic cancer treatment.

Immuneering's third quarter 2026 update provides context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 30, 2026 03:11 WIB: 106 of 150 priced health-sector US stocks rose, 44 fell. Notable movers include GILD at USD 169.20 (+6.28%), AMWL at USD 15.00 (+6.23%), and HRTX at USD 0.29 (-5.63%). Typical hold times range from 38 to 114 days, with varied Pluang order activity.

More News

iHerb adds eBay's Jordan Sweetnam to board to boost global eCommerce growth and customer experience.

iHerb adds eBay's Jordan Sweetnam to board to boost global eCommerce growth and customer experience.

iHerb Holdings appointed Jordan Sweetnam, eBay's Chief Commercial Officer, as an independent director to its board. Sweetnam brings extensive experience in global eCommerce, having held senior roles at eBay and Walmart, and will support iHerb's expan...

Company Fundamentals
Bullish
3 hours ago
Alnylam Pharmaceuticals shares drop over 28% after lowering 2026 sales guidance, prompting fraud investigation.

Alnylam Pharmaceuticals shares drop over 28% after lowering 2026 sales guidance, prompting fraud investigation.

Alnylam Pharmaceuticals announced on July 30, 2026, that it lowered its full-year 2026 sales guidance for its TTR product by about $200 million due to slower than expected market growth. This caused the stock to fall 28.31%, injuring investors. On Oc...

Market News
Bearish
4 hours ago
Hyperliquid (HYPE) token rises 3% in an hour, gains 17.28% in 24 hours amid heavy liquidations.

Hyperliquid (HYPE) token rises 3% in an hour, gains 17.28% in 24 hours amid heavy liquidations.

Hyperliquid (HYPE) token price increased by 3.00% within one hour on October 29, reaching $94.82 on Binance. Over the same 24-hour period, HYPE gained 17.28%, reflecting strong upward momentum. During this hour, significant liquidations occurred with...

Market News
Bullish
4 hours ago
Harley-Davidson seen overvalued at 27x P/E with weak earnings and limited growth outlook through 2027.

Harley-Davidson seen overvalued at 27x P/E with weak earnings and limited growth outlook through 2027.

Harley-Davidson is currently trading at a high valuation of 27 times its earnings despite weak operating income and declining sales forecasts projected through 2027. Recent improvements in retail and inventory have not translated into sustainable ear...

Analyst Insights
Bearish
4 hours ago
$5.57B stolen from Binance-linked wallets in possible record crypto hack; investigation ongoing.

$5.57B stolen from Binance-linked wallets in possible record crypto hack; investigation ongoing.

At least $5.57 billion in cryptocurrency was moved out of Binance-linked wallets across Ethereum, Bitcoin, and Tron blockchains in what appears to be a major security breach. Binance has not confirmed a hack but is actively investigating the potentia...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App